Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sucampo Pharma Inc (SCMP) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 538,620
  • Shares Outstanding, K 45,840
  • Annual Sales, $ 153,180 K
  • Annual Income, $ 33,370 K
  • 36-Month Beta 1.74
  • Price/Sales 2.54
  • Price/Cash Flow N/A
  • Price/Book 3.70

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.56 +11.27%
on 01/31/17
12.60 -6.75%
on 02/22/17
+0.65 (+5.86%)
since 01/24/17
3-Month
10.56 +11.27%
on 01/31/17
17.55 -33.05%
on 11/30/16
-3.95 (-25.16%)
since 11/23/16
52-Week
9.59 +22.52%
on 03/17/16
17.55 -33.05%
on 11/30/16
-1.50 (-11.32%)
since 02/24/16

Most Recent Stories

More News
Sucampo Announces Fourth Quarter and Full Year 2016 Earnings Call

Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its fourth quarter and full year 2016 financial results teleconference and webcast...

SCMP : 11.75 (+0.43%)
Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View

Shire's (SHPG) fourth-quarter results were encouraging with the company beating both top- and bottom-line estimates.

SCMP : 11.75 (+0.43%)
SHPG : 181.29 (-2.24%)
SNSS : 4.29 (+2.39%)
GSK : 41.56 (+0.17%)
Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook

Zoetis Inc. (ZTS) topped earnings estimates in the fourth-quarter of 2016 while revenues came in line. The company also narrowed its outlook for 2017 to account for currency impact.

SCMP : 11.75 (+0.43%)
ZTS : 53.88 (+0.56%)
SNSS : 4.29 (+2.39%)
GSK : 41.56 (+0.17%)
Prothena (PRTA) Reports Wider-than-Expected Loss in Q4

Prothena's wider-than-expected loss in the fourth quarter was disappointing.

SCMP : 11.75 (+0.43%)
PRTA : 53.45 (-1.67%)
RHHBY : 30.6000 (+0.20%)
SNSS : 4.29 (+2.39%)
Gilead (GILD) Announces Data on Combination Therapy for HIV

Gilead Sciences, Inc. (GILD) recently announced positive data from a phase II study on HIV cocktail therapy.

SCMP : 11.75 (+0.43%)
GILD : 69.94 (+0.82%)
ABBV : 62.09 (+0.24%)
GSK : 41.56 (+0.17%)
Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View

GlaxoSmithKline plc (GSK)'s fourth quarter beat estimates but the outlook for 2017 was weak amid a potential entry of generics for Advair.

ENZ : 6.66 (+1.22%)
SCMP : 11.75 (+0.43%)
SNSS : 4.29 (+2.39%)
GSK : 41.56 (+0.17%)
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Global Healthcare Conference

Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will participate in a fireside chat at the 2017 Leerink Global Healthcare Conference taking...

SCMP : 11.75 (+0.43%)
Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints

Gilead Sciences' (GILD) fourth quarter results beat on both earnings and sales but the guidance for 2017 was quite disappointing.

SCMP : 11.75 (+0.43%)
GILD : 69.94 (+0.82%)
ABBV : 62.09 (+0.24%)
BMY : 56.44 (+1.20%)
Mallinckrodt (MNK) Tops on Earnings in Transition Quarter

Mallinckrodt Public Limited Company (MNK) reported positive results for the transition quarter (Oct 1, to Dec 30, 2016) beating both sales and earnings expectations.

ENZ : 6.66 (+1.22%)
SCMP : 11.75 (+0.43%)
MNK : 53.38 (-2.00%)
SNSS : 4.29 (+2.39%)
Auris (EARS) Expands Pipeline with Intranasal Betahistine

Auris (EARS) announced that it has strengthened its pipeline by the addition of AM-125 as the third clinical-stage program, which allowed it to expand into the field of vestibular disorders.

SCMP : 11.75 (+0.43%)
LLY : 82.87 (+0.39%)
EARS : 0.94 (+2.17%)
SNSS : 4.29 (+2.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones...

See More

Support & Resistance

2nd Resistance Point 12.24
1st Resistance Point 11.99
Last Price 11.75
1st Support Level 11.51
2nd Support Level 11.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.